Home Biotechnology Innovent Biologics
I

Innovent Biologics

Profile managed by Bizz Id
China 2011

Description

Chinese biopharmaceutical company founded in 2011 that develops, manufactures and commercialises medicines in oncology, metabolic and cardiovascular disease, autoimmunity and ophthalmology. Its portfolio includes monoclonal antibodies, fusion proteins, antibody-drug conjugates and small molecules, with around twenty approved products. Listed on the Hong Kong Stock Exchange since 2018.

Products

46 products
Abemaciclib

Brand: VERZENIOS. Small-molecule CDK4/6 inhibitor. Launched.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Abemaciclib: see suppliers →

Adalimumab

Brand: SULINNO. Anti-TNF-α. Ankylosing spondylitis, psoriasis, rheumatoid arthritis, uveitis, pediatric plaque psoriasis, polyarticular JIA, Crohn's disease and pediatric Crohn's disease.

Aprobado China

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Adalimumab: see suppliers →

Bevacizumab

Brand: BYVASDA (Bevagen in Indonesia). Bevacizumab biosimilar, anti-VEGF-A. NSCLC, colorectal cancer, glioblastoma, HCC, ovarian/fallopian tube/peritoneal cancer, cervical cancer.

Aprobado China; Aprobado BPOM (Indonesia)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Bevacizumab: see suppliers →

Equecabtagene Autoleucel

Brand: FUCASO. BCMA CAR-T therapy. Relapsed or refractory multiple myeloma.

Aprobado NMPA

Filing submitted

Other

Verified on 2026-10-21

Fulzerasib

Brand: DUPERT (tablets). Oral small-molecule KRAS G12C inhibitor. KRAS G12C-mutated lung cancer.

Aprobado NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Fulzerasib: see suppliers →

IBI-115 (DLL3/CD3)

Biologic; target DLL3/CD3. Oncology. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-128 (XO)

Small molecule; target XO. Autoimmune. Pivotal / Phase 2/3.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3001 (EGFR/B7H3 ADC)

Biologic; target EGFR/B7H3 ADC. Oncology. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3002 (IL-4Rα/TSLP)

Biologic; target IL-4Rα/TSLP. Autoimmune. Phase 1b/2.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3003 (GPRC5D/BCMA/CD3)

Biologic; target GPRC5D/BCMA/CD3. Oncology. Pivotal / Phase 2/3.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3005 (EGFR/HER3 ADC)

Biologic; target EGFR/HER3 ADC. Oncology. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3009 (DLL3 ADC)

Biologic; target DLL3 ADC. Oncology. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3011 (IL-1RAP)

Biologic; target IL-1RAP. Autoimmune. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3013 (IL-15)

Biologic; target IL-15. Autoimmune. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3014 (PD-L1/TROP2 ADC)

Biologic; target PD-L1/TROP2 ADC. Oncology. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3016 (AGT)

Biologic; target AGT. Metabolic. Phase 1b/2.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-302 (VEGF/Complement)

Biologic; target VEGF/Complement. Ophthalmology. Pivotal / Phase 2/3.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3020 (CEACAM5 dp ADC)

Biologic; target CEACAM5 dp ADC. Oncology. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3026 (PD-1/IL-12)

Biologic; target PD-1/IL-12. Oncology. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3027 (IL-4Rα)

Biologic; target IL-4Rα. Autoimmune. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3028 (EGFR/C-met ADC)

Biologic; target EGFR/C-met ADC. Oncology. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3031 (TSHR/IGF-1R)

Biologic; target TSHR/IGF-1R. Ophthalmology. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3032 (Oral GLP-1R (daily))

Small molecule; target Oral GLP-1R (daily). Metabolic. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3035 (insulin)

Small molecule; target insulin. Metabolic. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3040 (Amylin)

Small molecule; target Amylin. Metabolic. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-3042 (Oral GLP-1R (weekly))

Small molecule; target Oral GLP-1R (weekly). Metabolic. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-324 (VEGF-A/Ang2)

Biologic; target VEGF-A/Ang2. Ophthalmology. Phase 1b/2.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-343 (CLDN18.2 ADC)

Biologic; CLDN18.2 ADC. Oncology. NDA stage (the site states 1 asset under NMPA review).

Solicitud presentada: NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

IBI-354 (HER2 ADC)

Biologic; target HER2 ADC. Oncology. Pivotal / Phase 2/3.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-355 (CD40L)

Biologic; target CD40L. Autoimmune. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

IBI-363 (PD-1/IL-2 α-bias)

Biologic; target PD-1/IL-2 α-bias. Oncology. Pivotal / Phase 2/3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ipilimumab N01

Brand: TABOSUN. Anti-CTLA-4 mAb. Neoadjuvant treatment of stage IIB-III resectable MSI-H/dMMR colon cancer, with sintilimab.

Aprobado China

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Limertinib

Oral third-generation small-molecule EGFR TKI.

Aprobado NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Limertinib: see suppliers →

Mazdutide

GCGR/GLP-1R dual agonist. Chronic weight management in adults with overweight or obesity; glycemic control in type 2 diabetes.

Aprobado NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Mazdutide: see suppliers →

Olverembatinib

Oral third-generation small-molecule TKI, BCR-ABL/KIT (incl. T315I). Chronic-phase or accelerated-phase CML.

Aprobado China

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Olverembatinib: see suppliers →

Pemigatinib

Brand: PEMAZYRE. Small-molecule selective FGFR1/2/3 inhibitor, jointly developed by Incyte and Innovent; Innovent commercializes in Chinese Mainland, Hong Kong, Macau and Taiwan. Cholangiocarcinoma.

Aprobado NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pemigatinib: see suppliers →

Picankibart

Brand: PECONDLE. Anti-IL-23p19 antibody developed in-house. Moderate-to-severe plaque psoriasis in adults.

Aprobado NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Picankibart: see suppliers →

Pirtobrutinib

Brand: JAYPIRCA (tablets). Small-molecule non-covalent (reversible) highly selective BTK inhibitor.

Aprobado FDA; Aprobado NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pirtobrutinib: see suppliers →

Quizartinib

Brand: VANFLYTA. Small-molecule FLT3 inhibitor. Launched.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Quizartinib: see suppliers →

Ramucirumab

Brand: CYRAMZA. Anti-VEGFR-2. Second-line advanced gastric/GEJ adenocarcinoma (with paclitaxel) in China; NSCLC, HCC, GC and CRC in the U.S.

Aprobado FDA; Aprobado NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ramucirumab: see suppliers →

Rituximab

Brand: HALPRYZA. Anti-CD20. Five indications in China including non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Aprobado China

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Rituximab: see suppliers →

Selpercatinib

Brand: Retevmo. Small-molecule RET inhibitor. RET-altered advanced NSCLC and thyroid cancer.

Aprobado FDA; Aprobado NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Selpercatinib: see suppliers →

Sintilimab

Brand: TYVYT. Fully human IgG4 anti-PD-1 mAb, co-developed with Eli Lilly in China. Hodgkin lymphoma, squamous and non-squamous NSCLC, HCC, esophageal carcinoma, gastric cancer, EGFR-TKI failure NSCLC, MSI-H/dMMR colon cancer (neoadjuvant, with ipilimumab N01), renal cell carcinoma (with fruquintinib).

Aprobado NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Sintilimab: see suppliers →

Tafolecimab

Brand: SINTBILO. Anti-PCSK9 antibody. Primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia.

Aprobado China

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Tafolecimab: see suppliers →

Taletrectinib Adipate

Brand: DOVBLERON (capsules). Small-molecule ROS1/NTRK inhibitor. Locally advanced or metastatic ROS1-positive NSCLC.

Aprobado NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Taletrectinib Adipate: see suppliers →

Teprotumumab N01

Brand: SYCUME. Anti-IGF-1R antibody. Thyroid eye disease.

Aprobado NMPA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free